SIBN Stock Overview
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SI-BONE, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.08 |
| 52 Week High | US$29.51 |
| 52 Week Low | US$14.84 |
| Beta | 1.22 |
| 1 Month Change | -0.46% |
| 3 Month Change | -24.64% |
| 1 Year Change | -31.30% |
| 3 Year Change | -56.84% |
| 5 Year Change | -9.97% |
| Change since IPO | -24.83% |
Recent News & Updates
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
Apr 01
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
Feb 29Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Feb 28Recent updates
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
Apr 01Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
Feb 29Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Feb 28Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Nov 12Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Aug 09Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Apr 20Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jan 01Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Sep 24SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
Apr 19Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Jan 05Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Oct 05Does SI-BONE (NASDAQ:SIBN) Have A Healthy Balance Sheet?
Jul 05Shareholder Returns
| SIBN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.0% | 1.8% | 1.2% |
| 1Y | -31.3% | -0.5% | 24.9% |
Return vs Industry: SIBN underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: SIBN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| SIBN volatility | |
|---|---|
| SIBN Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SIBN's share price has been volatile over the past 3 months.
Volatility Over Time: SIBN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 344 | Laura Francis | si-bone.com |
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion.
SI-BONE, Inc. Fundamentals Summary
| SIBN fundamental statistics | |
|---|---|
| Market cap | US$627.06m |
| Earnings (TTM) | -US$43.34m |
| Revenue (TTM) | US$138.89m |
4.5x
P/S Ratio-14.3x
P/E RatioIs SIBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIBN income statement (TTM) | |
|---|---|
| Revenue | US$138.89m |
| Cost of Revenue | US$29.47m |
| Gross Profit | US$109.42m |
| Other Expenses | US$152.76m |
| Earnings | -US$43.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 78.78% |
| Net Profit Margin | -31.20% |
| Debt/Equity Ratio | 21.3% |
How did SIBN perform over the long term?
See historical performance and comparison